Male breast cancer: A multicenter study in Aragon over 27 years

[Display omitted] Male breast cancer accounts for 1% of all breast cancers. Its low frequency leads to a lack of awareness, resulting in significant diagnostic delays. Additionally, this limits the available evidence, which primarily uses diagnostic-therapeutic algorithms based on women. To analyze...

Full description

Saved in:
Bibliographic Details
Published in:Cirugia española (English ed.) 2024-09
Main Authors: Dobato Portoles, Olga, Aparicio Lopez, Daniel, Ibañez Carreras, Reyes, Aguirre Ortega, Elena, Eizaguirre Zarza, Beatriz, García Mur, Carmen, Carrasquer Puyal, Aurora, Cebollero Benito, María Pilar, Comín Novella, Laura Isabel, Allue Cabañuz, Marta, Martinez Ubieto, Fernando, Sousa Domínguez, Ramón, Torcal Aznar, Javier, Casamayor Franco, Carmen
Format: Article
Language:English
Subjects:
Breast surgery
Cirugía mamaria
Cáncer de mama varón
Hormone therapy
Hormonoterapia
Male breast cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Male breast cancer accounts for 1% of all breast cancers. Its low frequency leads to a lack of awareness, resulting in significant diagnostic delays. Additionally, this limits the available evidence, which primarily uses diagnostic-therapeutic algorithms based on women. To analyze the prevalence, clinical presentation, anatomical and pathological characteristics, and prognosis of male breast cancer using one of the largest series available. Secondarily, to compare our data with studies conducted in women. A multicenter, observational, descriptive, retrospective study was conducted in the autonomous community of Aragon, Spain, from 1995 to 2022 including men with a pathological diagnosis of breast cancer. A total of 148 patients were included, with a prevalence of 1%. The most common clinical presentation was a palpable retroareolar mass. Invasive ductal carcinoma was the most frequent type (88.89%), and luminal B was the predominant subtype (47.76%). Surgery was the most utilized treatment; mastectomy was performed in 90.34% and AL in 46.89%. At diagnosis, 52.46% had extramammary involvement. The recurrence rate was 24.1%, and the mortality attributed to the disease was 14.6%. There is a high rate of metastatic involvement at diagnosis, a high percentage of mutilating surgeries, and a high number of recurrences compared to available studies on males. Additionally, a worse prognosis is observed compared to breast cancer in women, despite these tumors having a less aggressive molecular subtype. These findings highlight the importance of conducting studies focused on men to develop specific protocols. el cáncer de mama en el varón representa el 1% de todos los cánceres de mama. Su baja frecuencia conlleva a la ausencia de conciencia que implica un retraso diagnóstico significativo. Además, limita la evidencia disponible utilizando algoritmos diagnóstico-terapéuticos basados en mujeres. analizar la prevalencia, presentación clínica, características anatomo-patológicas y pronóstico del cáncer de mama en varones con una de las series más largas disponibles. Secundariamente, comparar nuestros datos con estudios realizados en mujeres. Se realizó un estudio multicéntrico, observacional, descriptivo y retrospectivo en la CCAA de Aragón, abarcando desde 1995 a 2022, incluyendo varones con diagnóstico anatomopatológico de cáncer de mama. se incluyeron 148 pacientes, con una prevalencia del 1%. La presentación clínica más común fue una masa palpable r
ISSN:2173-5077
2173-5077
DOI:10.1016/j.cireng.2024.09.001